Current prophylactic HPV vaccines and gynecologic premalignancies.

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Cervical cancer is a significant global health concern, primarily caused by persistent infection with high-risk human papillomavirus (HPV) types.
• HPV vaccines Cervarix and Gardasil are crucial interventions for preventing HPV-related diseases, including cervical cancer.

Purpose of the Study:

• To review and compare the efficacy, cross-protection, and immunological response of HPV vaccines Cervarix and Gardasil.
• To assess the long-term impact of these vaccines on cervical intraepithelial neoplasia (CIN) and the need for excisional therapies.

Main Methods:

• Comparative analysis of clinical trial data for Cervarix and Gardasil.
• Review of immunological studies assessing antibody titers, mucosal immunity, and B memory cell response.
• Evaluation of safety data, including adverse events.

Main Results:

• Both vaccines show over 90% efficacy against HPV 16/18-related CIN 2+ in seronegative women aged 16-26.
• Cervarix offers superior cross-protection against HPV 31, 45, and 33 compared to Gardasil.
• Cervarix is associated with a nearly 70% reduction in CIN 2+ excisional therapies, versus 40% for Gardasil, with longer documented efficacy (6.4 vs 5 years).
• Cervarix elicits higher neutralizing antibody titers and a stronger mucosal and B memory cell response than Gardasil.
• Both vaccines have comparable safety profiles, with common injection site reactions and rare serious adverse events reported.

Conclusions:

• HPV vaccines, particularly Cervarix, are highly effective in preventing high-grade cervical lesions and reducing the need for invasive procedures.
• Cervarix demonstrates broader protection and a more robust immunological response, suggesting potential for greater long-term public health impact.
• Continued surveillance and research are essential to fully understand the long-term benefits and safety of HPV vaccination.